Table 2.
Time to Treatment Switch and Distance Visual Acuity According to Whether Treatment Was Switched
| Characteristic | Did Not Switch‖ (n = 277) |
Switched Treatments‖ (n = 81) |
No Treatment Since IVAN Exit (n = 174) |
Overall (n = 532) |
||||
|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| Time (yrs) | ||||||||
| IVAN exit to switch | 2.7 | (2.0–3.5) | ||||||
| Switch to end of SE monitoring | 2.3 | (1.6–2.8) | ||||||
| IVAN exit to end of SE monitoring | 3.5 | (1.7–4.7) | 5.0 | (4.4–5.7) | 1.0 | (0.1–2.2) | 2.9 | (1.1–4.7) |
| DVA | ||||||||
| IVAN exit∗ | 73.0 | (59.5–80.0) | 77.0 | (70.0–83.0) | 67.0 | (39.0–77.0) | 72.0 | (56.0–80.0) |
| Date of switch†¶ | 64.0 | (54.5–73.0) | ||||||
| End of SE monitoring‡ | 58.0 | (33.0–73.0) | 60.0 | (44.0–69.0) | 58.0 | (33.0–73.0) | 58.0 | (34.0–73.0) |
DVA = distance visual acuity; IQR = interquartile range; IVAN = Inhibition of VEGF in Age-related choroidal Neovascularisation; SE = study eye.
∗
Data missing for 1 patient (1 did not switch, 0 switched treatments, and 1 no injections).
†
Data missing for 17 patients (−, 17 switched treatments).
‡
Data missing for 33 patients (0 did not switch, 0 switched treatments, 33 no injections).
‖
Switches include ranibizumab to aflibercept (n = 78) and bevacizumab to aflibercept (n = 3).
¶
Median predicted DVA from mixed effects model (Table 3) at median time to switch (2.7 years) is 61.2 for non-switchers.